Galapagos signs new compound management agreement

Mechelen, Belgium; 30 June 2008 – Galapagos NV (Euronext: GLPG) announces today that its service division BioFocus DPI will provide compound management and related services to Sepracor Inc. (NASDAQ: SEPR), a leader in respiratory and central nervous system disorder medicines.  Total contract value for Galapagos is €1 million ($1.5 million).  Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library, and plate and replicate these compounds for a period of three years.  Services will be provided by BioFocus DPI’s compound management facility in South San Francisco, USA.
“We welcome Sepracor as a new client to BioFocus DPI,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.  “Our compound management site has been able to broaden its customer base over the last year, and with this agreement we further expand our list of pharma companies.”  
About BioFocus DPI compound management
BioFocus DPI provides compound management services at its South San Francisco (USA) site, home to the National Institutes of Health Molecular Libraries Small Molecule Repository.  BioFocus DPI offers the following compound management services: selection and sourcing, analysis, storage, plating and reformatting, purification, distribution.  It employs state of the art equipment and compound handling techniques to ensure sample integrity.  Customers include the government institutes NIH and Environmental Protection Agency as well as a number of biotech and pharmaceutical companies.
About Galapagos
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis.  Its BioFocus DPI division offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.  BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs 460 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More information about Galapagos and BioFocus DPI can be found at  and
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.